Navigation Links
US FDA Admits Risks of Mercury Dental Fillings, Settles Lawsuit
Date:6/5/2008

Statement of Michael Bender, Plaintiff

WASHINGTON, June 5 /PRNewswire-USNewswire/ -- "After 32 years of delay, the Food and Drug Administration has finally agreed to comply with the law and set a date to classify mercury amalgam as a substance that poses a health risk to pregnant women and unborn babies, and children. This about-face resulted from settling, earlier this week, our lawsuit, Moms Against Mercury et al. v. Von Eschenbach, Commissioner, et al. The FDA must now finish classification within one year of the close of the public comment period on its amalgam policy, that is, by July 28, 2009. The FDA also agreed to and, with uncharacteristic speed, has already changed its website on mercury amalgam -- dramatically.

Gone are all of FDA's claims that no science exists that amalgam is unsafe, or that other countries have acted for environmental reasons only, or that the 2006 FDA advisory panel affirmed amalgam's safety, all of which are untrue. Instead, the FDA has moved to a more neutral course, while still recognizing the serious health risks posed by amalgam in particular for children and unborn children, for pregnant women, and for those with mercury immuno-sensitivity.

The Updated June 3, 2008 FDA website (see: http://www.fda.gov/cdrh/consumer/amalgams.html) now states, for example:

"Dental amalgams contain mercury, which may have neurotoxic effects on the nervous systems of developing children and fetus."

"Pregnant women and persons who may have a health condition that makes them more sensitive to mercury exposure, including individuals with existing high levels of mercury bioburden, should not avoid seeking dental care, but should discuss options with their health practitioner."

In September 2006, an advisory panel to the FDA reviewed FDA's research and heard presentations from the public about the benefits and risks of mercury and amalgam. The joint committee concluded with personal recommendations by the members. These include that FDA should:

Consider informed consent for patients receiving amalgam

Consider labeling changes restricting its use in pregnant woman and children

Consider the relevancy of the "precautionary principle"

You can read the summary of the FDA advisory panel meeting at: http://www.fda.gov/cdrh/meetings/090606-summary.html

The FDA website now also states that "Some other countries follow a 'precautionary principle' and avoid the use of dental amalgam in pregnant women. The FDA provides links to advice about dental amalgams from regulatory agencies in other countries:

Canada: http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/1996/1996_63_e.html

France: http://afssaps.sante.fr/ang/pdf/amalgam.pdf

Sweden: http://www.kemi.se/templates/Page.aspx?id=5233 "

The plaintiffs included a team of four nonprofit groups, two public officials, three dental professionals, and two consumer victims: Moms Against Mercury (Amy Carson and Angela Medlin), Connecticut Coalition for Environmental Justice (Dr. Mark Mitchell), Oregonians for Life (Mary Starrett), mercury expert Michael Bender (as a of the Vermont Advisory Committee on Mercury Pollution), Arizona Senator Karen Johnson, Dr. Andy Landerman, Dr. Corrie Crowe, dental assistant Karen Palmer, consumer advocates Linda Brocato and Anita Vazquez Tibau, and Consumers for Dental Choice.

For More Information: http://www.mercurypolicy.org


'/>"/>
SOURCE Mercury Policy Project
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sutter Admits: Closing St. Lukes Likely to Reduce Charity Care
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Informational handout key to giving parents a better understanding of CT radiation risks
4. Stanford study highlights cost-effective method of lowering heart disease risks
5. Hispanic Teens Take More Skin Cancer Risks
6. Smoking increases risks for head and neck cancers for men and women
7. Case Management Cost-Effective Way to Cut Heart Risks
8. National Council of Negro Women (NCNW) Partners With Sherwin-Williams to Target Lead Risks in Neglected Housing
9. Diabetes Drug Avandia Boosts Heart Risks: Study
10. Federal research plan to determine nanotech risks fails to deliver
11. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... Beleza Medspa has initiated a new program ... is the first time that Coolsculpting is being used for for more than just ... ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
(Date:5/27/2016)... ... May 27, 2016 , ... With ... pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center is ... of successfully certified products, services and staff. , Validation Center is ISO17025 accredited ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... thousands of defective respirators, according to court documents and SEC filings. A ... and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles County, ...
(Date:5/26/2016)... Washington, D.C. (PRWEB) , ... May 26, 2016 , ... ... the men and women who lost their lives in military battle for the country. ... discount cards in 2015 to provide more programs that empower independence for disabled military ...
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line of ... Warner, New Hampshire at the MadgeTech headquarters. With products sold in more than 100 ... government agencies, including NASA. , In 2012, NASA strategically set up 17 RHTemp101A ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... and co-development agreement with Therawis Diagnostics GmbH to develop and ... to develop and market PITX2 as a marker to predict ... breast cancer patients. "We are pleased to partner ...
(Date:5/25/2016)... , May 25, 2016  According to Kalorama ... $381 billion in 2015.  Though these are challenging ... of opportunity for success for companies that remain ... search of new growth prospects medical device companies ... research and development (R&D) than do companies in ...
Breaking Medicine Technology: